+316.7%
PANW vs MRNA
-67.9%
+384.5%
-36.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.3% | +5.4% | -7.7% | -2.5% |
| 7D | -0.8% | -1.1% | +0.3% | -0.8% |
| 30D | -14.6% | +126.1% | -140.7% | -20.1% |
| 3M | +18.3% | +190.0% | -171.7% | +6.9% |
| 6M | +100.5% | +157.2% | -56.7% | +83.1% |
| YTD | +79.5% | +388.2% | -308.7% | +49.6% |
| 1Y | +66.7% | +467.0% | -400.3% | +35.3% |
| 3Y | +161.2% | +36.1% | +125.2% | +142.2% |
| All | +316.7% | -67.9% | +384.5% | +317.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling